The authors describe the development of acute psychoses in four patients treated with bupropion, a unicyclic aminoketone antidepressant. In two of the cases the psychoses seemed to be affected by dose. The mechanism responsible for the psychotic reactions is unclear, although it may involve perturbation of dopaminergic systems. On the basis of their experience, the authors offer recommendations regarding the clinical use of bupropion.
[Show abstract][Hide abstract] ABSTRACT: Visual hallucinations occur in diverse clinical circumstances including ophthalmologic diseases, neurologic disorders, toxic and metabolic disorders and idiopathic psychiatric illnesses. Their content, duration and timing relate to their cause and provide useful differential diagnostic information. Hallucinations must be distinguished from delusions and confabulation. A systematic approach to differentiating among hallucinatory syndromes may improve diagnostic accuracy.
Western Journal of Medicine 02/1987; 146(1):46-51.
[Show abstract][Hide abstract] ABSTRACT: The authors performed a double-blind study in which 38 inpatients diagnosed as schizophrenic with depressive symptoms were treated with either bupropion and thiothixene or placebo and thiothixene. Of the 36 patients who completed 4 weeks of study treatment, the placebo-thiothixene treated patients did significantly better than the bupropion-thiothixene treated patients on BPRS total scores as well as anxiety and depression items. The bupropion-thiothixene treated patients reported significantly more dry mouth and constipation than the placebo-thiothixene treated group, whereas the placebo-thiothixene treated group reported more frequent occurrences of increased appetite, menstrual disturbance, and decreased sex drive. Neither group differed on ratings of pseudoparkinson or dyskinetic signs. The antidepressant bupropion as an adjunct to thiothixene was less effective in the treatment of depressed schizophrenic patients than the antipsychotic alone and appeared to inhibit the therapeutic effects of thiothixene primarily in the depressive symptoms of the syndrome.
Drug Development Research 01/1988; 12(3‐4):259 - 266. DOI:10.1002/ddr.430120308 · 0.77 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.